EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

The Role of HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer : A Systematic Review of Randomized Controlled Trials

Muhamad Luthfi Asyhar, Yuke Aulia Novianti, Mia Maya Aziza, Bernita Nur Cahyani, Theresia Murniwati Situmorang, Zia Faradila, Risa Rahmadina, Charles Sanjaya

The Indonesian Journal of General Medicine · 30.07.2026 · 43 (1) · 1-69

DOI: 10.70070/3gv2zv39 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Indonesian Journal of General Medicine, online erschienen am 30.07.2026. Verfasst von Muhamad Luthfi Asyhar und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Human epidermal growth factor receptor 2 (HER2) amplification characterises approximately 15–20% of invasive breast carcinomas and was historically associated with rapid visceral dissemination, central nervous system (CNS) tropism, and short survival. Over two decades, HER2-directed monoclonal antibodies, antibody–drug conjugates (ADCs), and tyrosine kinase inhibitors (TKIs) have progressively redefined the natural history of HER2-positive metastatic breast cancer (MBC). This systematic review was undertaken to synthesise, within a single comprehensive evidence framework, the magnitude, consistency, and safety trade-offs of HER2-targeted therapy across all treatment lines.

Methods

A systematic review of randomized controlled trials (RCTs) was conducted in accordance with PRISMA 2020. Eligible studies were phase II or III RCTs enrolling adults with HER2-positive advanced or MBC receiving at least one HER2-targeted agent. Two reviewers independently screened, extracted data, appraised risk of bias using Cochrane RoB 2, and rated certainty with GRADE. Effect estimates (hazard ratios [HRs] and risk ratios [RRs]) were pooled using DerSimonian–Laird random-effects inverse-variance models.

Results

Twenty-three RCTs comprising 9,808 randomized patients met eligibility. Across 18 trials, the pooled progression-free survival (PFS) HR for HER2-directed intensification versus control was 0.55 (95% CI 0.48–0.63; p

Zitieren

APA

Asyhar, M. L., Novianti, Y. A., Aziza, M. M., Cahyani, B. N., Situmorang, T. M., Faradila, Z., Rahmadina, R., & Sanjaya, C. (2026). The Role of HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer : A Systematic Review of Randomized Controlled Trials. The Indonesian Journal of General Medicine, 43(1), 1-69. https://doi.org/10.70070/3gv2zv39

Vancouver

Asyhar ML, Novianti YA, Aziza MM, Cahyani BN, Situmorang TM, Faradila Z, et al. The Role of HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer : A Systematic Review of Randomized Controlled Trials. The Indonesian Journal of General Medicine. 2026;43(1):1-69. doi:10.70070/3gv2zv39

BibTeX
@article{Asyhar2026,
  author = {Asyhar, Muhamad Luthfi and Novianti, Yuke Aulia and Aziza, Mia Maya and Cahyani, Bernita Nur and Situmorang, Theresia Murniwati and Faradila, Zia and Rahmadina, Risa and Sanjaya, Charles},
  title = {The Role of HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer : A Systematic Review of Randomized Controlled Trials},
  journal = {The Indonesian Journal of General Medicine},
  year = {2026},
  volume = {43},
  number = {1},
  pages = {1--69},
  doi = {10.70070/3gv2zv39}
}
Kostenlos starten →